Garrett Winslow Biography and Net Worth

General Counsel of Galecto

Presently, Garrett M. Winslow holds the position of Senior Vice President & General Counsel of Galecto, Inc.

In his past career he was Principal at Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC and Secretary, Vice President-Legal & General Counsel at Spring Bank Pharmaceuticals, Inc.

Garrett M. Winslow received a graduate degree from Boston University School of Law, a graduate degree from Suffolk University Law School and an undergraduate degree from the University of Washington.

What is Garrett Winslow's net worth?: The estimated net worth of Garrett Winslow is at least $35,125.00 as of November 20th, 2020. Mr. Winslow owns 6,250 shares of Galecto stock worth more than $35,125 as of November 24th. This net worth evaluation does not reflect any other investments that Mr. Winslow may own. Learn More about Garrett Winslow's net worth.
How old is Garrett Winslow?: Mr. Winslow is currently 45 years old. There are 2 older executives and no younger executives at Galecto. The oldest executive at Galecto is Dr. Hans T. Schambye M.D., Ph.D., Co-Founder, President, CEO & Director, who is 58 years old. Learn More on Garrett Winslow's age.
How do I contact Garrett Winslow?: The corporate mailing address for Mr. Winslow and other Galecto executives is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. Galecto can also be reached via phone at 45-7070-5210. Learn More on Garrett Winslow's contact information.
Has Garrett Winslow been buying or selling shares of Galecto?: Garrett Winslow has not been actively trading shares of Galecto within the last three months. Most recently, on Friday, December 3rd, Garrett Winslow bought 80 shares of Galecto stock. The stock was acquired at an average cost of $62.00 per share, with a total value of $4,960.00. Learn More on Garrett Winslow's trading history.
Who are Galecto's active insiders?: Galecto's insider roster includes Jonathan Freve (CFO), Bertil Lindmark (Insider), Hans Schambye (CEO), and Garrett Winslow (General Counsel). Learn More on Galecto's active insiders.

Garrett Winslow Insider Trading History at Galecto

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/3/2021	Buy	80	$62.00	$4,960.00

Garrett Winslow Buying and Selling Activity at Galecto

Galecto Company Overview

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Today's Range

Now: $5.62

$5.52

$6.19

50 Day Range

MA: $8.52

$5.62

$14.09

2 Week Range

Now: $5.62

$5.52

$23.50

Volume

37,027 shs

Average Volume

16,658 shs

Market Capitalization

$7.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Watch this before it gets removed

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.